Diligence memo · auto-generated · as of July 2, 2026
Integrated Oncology Network Holdco, LLC
Integrated Oncology Network Holdco, LLC looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Integrated Oncology Network Holdco, LLC operates in Pharma, based in EVANSTON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Integrated Oncology Network Holdco, LLC has raised $70M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $70M on 2019-06-24.
Most recent recorded round closed around 2019-06-24.
Valuation (modeled)modeled
Provath models Integrated Oncology Network Holdco, LLC at approximately $2.5B (range $227M–$6.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.22× the median modeled value of Series C Pharma companies in 2019–2021 (7 peers) — value vs value, same stage and era. Within the normal band (122% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 7.0 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 87% of Pharma peers (310 compared).
Modeled value ranks above 96% of those peers.
Closest niche peers: Ansun Biopharma, Inc., Tallac Therapeutics, Inc., Elevation Oncology, Inc., CERo Therapeutics, Inc., Levo Therapeutics, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.